Paper23948975
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Masuda H and 11 others. Clin Cancer Res, 2013. Cited by 570 papers, by iCite.
Cite this record
ConductScience Library. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Papers, record 23948975. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23948975
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Genetic Heterogeneity | Major topic |
| Triple Negative Breast Neoplasms | Major topic |
| Adult | |
| Aged | |
| Cluster Analysis | |
| Female | |
| Gene Expression Profiling | |
| Humans | |
| Middle Aged | |
| Neoplasm Grading | |
| Neoplasm Staging | |
| Recurrence | |
| Reproducibility of Results | |
| Treatment Outcome |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| R01 CA123318 | NCI NIH HHS | United States | R01CA123318 | PubMed and NIH | NIH RePORTER |
| CA123318 | NCI NIH HHS | United States | R01CA123318 | PubMed and NIH | NIH RePORTER |
| CA016672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| P30CA016672 | NIH | NIH RePORTER |
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17513820 | Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17513820 | PubMed |
| 2 | 12829800 | Repeated observation of breast tumor subtypes in independent gene expression data sets. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/12829800 | PubMed |
| 3 | 17438091 | The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17438091 | PubMed |
| 4 | 22508812 | Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22508812 | PubMed |
| 5 | 20813035 | Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. | Breast Cancer Res | 2010 | https://conductscience.org/library/papers/20813035 | PubMed |
| 6 | 19204204 | Supervised risk predictor of breast cancer based on intrinsic subtypes. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19204204 | PubMed |
| 7 | 19047281 | Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19047281 | PubMed |
| 8 | 17785706 | Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17785706 | PubMed |
| 9 | 16115903 | Breast cancer molecular subtypes respond differently to preoperative chemotherapy. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/16115903 | PubMed |
| 10 | 11553815 | Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11553815 | PubMed |
| 11 | 16896004 | Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16896004 | PubMed |
| 12 | 21558518 | A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. | JAMA | 2011 | https://conductscience.org/library/papers/21558518 | PubMed |
| 13 | 21421860 | Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. | J Natl Cancer Inst | 2011 | https://conductscience.org/library/papers/21421860 | PubMed |
| 14 | 22872785 | TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. | Cancer Inform | 2012 | https://conductscience.org/library/papers/22872785 | PubMed |
| 15 | 17387718 | Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. | Cancer | 2007 | https://conductscience.org/library/papers/17387718 | PubMed |
| 16 | 12582260 | Summaries of Affymetrix GeneChip probe level data. | Nucleic Acids Res | 2003 | https://conductscience.org/library/papers/12582260 | PubMed |
| 17 | 20697068 | Genomic index of sensitivity to endocrine therapy for breast cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20697068 | PubMed |
| 18 | 16951390 | Molecular classification of breast cancer: limitations and potential. | Oncologist | 2006 | https://conductscience.org/library/papers/16951390 | PubMed |
| 19 | 17493263 | Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. | Genome Biol | 2007 | https://conductscience.org/library/papers/17493263 | PubMed |
| 20 | 18250347 | Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18250347 | PubMed |
Cited by410
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 570 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42984587 | Novel aptamer-based strategies for addressing aggressive and heterogeneous triple-negative breast cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42984587 | PubMed |
| 42938935 | Clinical Challenges in Triple-Negative Breast Cancer (TNBC): Current Treatment Options, Their Limitations, and Emerging Perspectives. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938935 | PubMed |
| 42882450 | Distinct Mitochondrial Recovery Dynamics Following Taxol Removal in Triple-Negative Breast Cancer Cells. | Cells | 2026 | https://conductscience.org/library/papers/42882450 | PubMed |
| 42865910 | Tumor microenvironment-driven immune evasion in triple-negative breast cancer: mechanisms, clinical challenges, and therapeutic opportunities. | Front Immunol | 2026 | https://conductscience.org/library/papers/42865910 | PubMed |
| 42769774 | Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape. | Oncol Res | 2026 | https://conductscience.org/library/papers/42769774 | PubMed |
| 42743833 | Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal. | Breast | 2026 | https://conductscience.org/library/papers/42743833 | PubMed |
| 42558411 | Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42558411 | PubMed |
| 42394702 | Homologous recombination pathway alterations in basal-like breast cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42394702 | PubMed |
| 42380524 | Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application. | Cancer Causes Control | 2026 | https://conductscience.org/library/papers/42380524 | PubMed |
| 42319344 | Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. | Oncoimmunology | 2026 | https://conductscience.org/library/papers/42319344 | PubMed |
| 42253979 | Spatial organization of the tumor immune microenvironment in LAR+ triple-negative breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42253979 | PubMed |
| 42182220 | Integrated Collagen Architecture and Composition Improve Risk Stratification in Triple-Negative Breast Cancer. | bioRxiv | 2026 | https://conductscience.org/library/papers/42182220 | PubMed |
| 42093035 | The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer. | Breast Cancer Res | 2026 | https://conductscience.org/library/papers/42093035 | PubMed |
| 42033778 | Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma. | Oncologist | 2026 | https://conductscience.org/library/papers/42033778 | PubMed |
| 41977343 | Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977343 | PubMed |
| 41975515 | Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer. | Genome Biol | 2026 | https://conductscience.org/library/papers/41975515 | PubMed |
| 41968987 | Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer. | Cancer Biol Med | 2026 | https://conductscience.org/library/papers/41968987 | PubMed |
| 41889401 | Development and validation of an interpretable ensemble model for predicting androgen receptor status in triple-negative breast cancer: a multi-center study. | Front Oncol | 2026 | https://conductscience.org/library/papers/41889401 | PubMed |
| 41885969 | Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer. | Breast Cancer Res Treat | 2026 | https://conductscience.org/library/papers/41885969 | PubMed |
| 41800049 | The impacts of androgen receptor on treatment response and survival in triple-negative breast cancer treated with neoadjuvant chemotherapy: a single-center retrospective study. | Front Oncol | 2026 | https://conductscience.org/library/papers/41800049 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 | NCBI Gene |
| CADM1 | 23705 | PubTator's text mining | https://conductscience.org/library/genes/23705 | NCBI Gene |
| EGF | 1950 | PubTator's text mining | https://conductscience.org/library/genes/1950 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| IGF1R | 3480 | PubTator's text mining | https://conductscience.org/library/genes/3480 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
| PTPRF | 5792 | PubTator's text mining | https://conductscience.org/library/genes/5792 | NCBI Gene |
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23948975
GET https://conductscience.org/api/papers/v1/23948975/references?page=2